Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of High-fat Diet on AL8326 Pharmacokinetics
NCT05486598Phase 1Unknown
- Sponsor
- Advenchen Laboratories
- Start
- Jun 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AL8326 in small cell lung cancer (SCLC) (2 arms), sponsored by Advenchen Laboratories. Primary endpoints: Area Under the Curve from time zero to last measurable concentration, Area Under the Curve from time zero to infinity and 1 more. Status: unknown.
02
Drugs
AL8326
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05486598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05486598.